Introduction {#Sec1}
============

Gemcitabine is a chemotherapy agent frequently elected to treat solid tumors, including breast, colonic, ovarian, pancreatic, and non-small cell lung cancers \[[@CR1]--[@CR12]\]. Its side effect is unpredictable and lung toxicity has been observed \[[@CR1]--[@CR13]\]. Metastatic gallbladder cancer is a complex and uncommon event \[[@CR14]--[@CR17]\]. In this report, we describe a case of gallbladder metastatic colonic adenocarcinoma associated with fatal gemcitabine-induced pulmonary toxicity and discuss the histologic appearance of this dysfunction.

Case report {#Sec2}
===========

A 72-year-old male patient experienced an incidental diagnostic of tubular adenocarcinoma inside the gallbladder after elective laparoscopic cholecystectomy for chronic cholecystitis. CT scan and ultrasonographic evaluations performed before surgery were negative. Four days after cholecystectomy, he was submitted to laparotomy aiming radical resection; however, peritoneal carcinomatosis was observed. The patient was submitted to a tumor screening and a Pet scan pointed out a hot-spot in the left colon. This lesion was removed by colonoscopy and a histological examination confirmed a margin-free resection of a tubular adenocarcinoma. The patient was finally scheduled to receive three sections of gemcitabine (1,600 mg/m^2^) once a week. Three weeks after the completion of chemotherapy, he developed an important respiratory distress requiring ventilator support. A helicoidal CT scan showed bilateral and diffuse lung infiltrates (Fig. [1](#Fig1){ref-type="fig"}). A surgical lung biopsy was done and an accelerated usual interstitial pneumonia (UIP) (Fig. [2](#Fig2){ref-type="fig"}), consistent with drug-induced toxicity, was observed. The patient presented with progressive impairment of respiratory function, coagulopathy, hypotension, and acute renal failure despite the use of methylprednisolone pulse therapy, large spectrum antimicrobial therapy, and full respiratory, hemodynamic and dialytic support. He died 1 month later. To assess the probability that the event was caused by gemcitabine we computed a Naranjo et al. \[[@CR18]\] average point score, which is based on the direction of causality between the drug and the manifestation of adverse effects. Naranjo's method estimates gemcitabine as the probable cause of pulmonary toxicity in the current report.Fig. 1**a** Coronal reformatted images demonstrate involvement of all lung zones and predominantly upper lobe distribution of the ground-glass opacities and areas of consolidation. Also noted are reticulation and small cysts in the subpleural and basal regions of the lungs. **b** High-resolution CT image at the level of the main bronchi shows extensive bilateral ground-glass opacities and dependent areas of consolidation. Some emphysema can also be seenFig. 2Lung surgical biopsy specimen showing accelerated usual interstitial pneumonia (*UIP*). A characteristic area of honeycomb change is shown at low magnification (**a**). At lower left corner (**a**), the adjacent alveolar septa are homogeneously thickened by fibroblast and chronic inflammation. Higher magnification of area showed in lower left corner (**b**, **c**) highlights the fibroblasts and chronic inflammation within alveolar septa and shows associated hyaline membranes (*arrow*). The appearance coincides with the organizing stage of DAD. Note also the squamous metaplasia (*arrows*) of bronchiolar epithelium from adjacent honeycomb area (**d**). This finding is another sign of superimposed acute lung injury

Comments {#Sec3}
========

There are several papers reporting pulmonary toxicity due to gemcitabine used as a single agent \[[@CR1]--[@CR8]\] or in combination with other antineoplastic agents \[[@CR9]--[@CR13]\]. The treatment of this event includes early use of steroid therapy administered either as pulses or continuously \[[@CR1]\], mainly using methylprednisolone; nevertheless, most cases have a dramatic and fatal evolution. Our patient obtained fatal evolution in spite of the use of steroids as recommended in the literature.

Belknap et al. \[[@CR3]\], reviewed data from spontaneous reports to Research on Adverse Drug Events and Reports of pharmacovigilance (RADAR) program and appraised the clinical feature of gemcitabine-associated severe acute lung injury. Among 178 reports of gemcitabine-induced pulmonary injury (55 from clinical trials and 92 from spontaneous reports) dyspnea, fever, and pulmonary infiltrate were the most frequent symptoms of gemcitabine-induced pulmonary injury \[[@CR3]\]. The median time to the diagnosis of this toxicity is 48 days (range 1--529) after initiation of gemcitabine.

Taxanes, docetaxel, and paclitaxel were the most frequent co-administered chemotherapies \[[@CR3]\]. Eleven phase II or phase III clinical trials enrolling 317 patients identified pulmonary injury rates greater than 10% \[[@CR3]\]. Highest rates of this toxicity (22 and 42%) were observed in phase III clinical trials in which patients with Hodgkin's disease were treated with gemcitabine and bleomycin \[[@CR3]\].

The authors concluded that high rates of gemcitabine-associated severe lung injury were observed, mainly when gemcitabine was combined with other agents that can also cause lung injury \[[@CR3]\]. Just recently, Arrieta et al. \[[@CR13]\], observed that radiotherapy and gemcitabine for locally advanced non-small cell lung cancer is associated with excessive pulmonary toxicity.

Differently, Czarnecki and Voss \[[@CR12]\] reviewed records of patients with pulmonary toxicity at FDA freedom of information (FDA-FOI) database and observed that there was no substantial difference in pulmonary toxicity with the combination of gemcitabine and taxanes in comparison with gemcitabine alone. Indeed, gemcitabine-induced pulmonary toxicity is a dramatic condition. In the current case, the patient presented with rapidly progressive respiratory failure and the lung biopsy showed an accelerated UIP complicated by superimposed acute lung injury. Most reported cases have occurred in patients with known UIP, but the lesion can occur in patients with clinically unrecognized UIP \[[@CR18]\]. The etiology of acute lung injury in UIP is unknown, but most cases are assumed to represent an inherent part of the natural history of UIP. Histologically, however, the changes cannot be separated from other causes of acute lung injury (such as viral infections, aspiration, sepsis, drug reactions, or toxic inhalants), and it is entirely possible that some cases may represent reactions to clinically unrecognized extrinsic lung insults \[[@CR19]\]. Pathologically, the diagnosis is not usually difficult if all microscopic changes are taken into consideration. Classically, there are easily recognizable areas of UIP with patchwork pattern and honeycomb change. Focus of diffuse alveolar damage (DAD) recognizable by larger and more confluent interstitial fibroblast proliferation smaller than fibroblast foci of UIP are usually present \[[@CR19]\]. Hyaline membranes are also present and they make easy diagnosis. Other findings of the diagnosis include squamous metaplasia in bronchiolar epithelium lining honeycomb areas. In the current case, Naranjo's method identified gemcitabine as the probable agent of pulmonary toxicity.

The liver is the most common site of metastatic dissemination of a colonic tumor; however, a tumor from this region is very rare. In fact, this is the first report of metastasize inside the gallbladder from a tumor of colon origin. There are few reports describing gallbladder metastasize from other origins \[[@CR13]--[@CR16]\]. The prognostic of these patients was very poor with most of them achieving \<1-year survival.

In summary, physicians should suspect pulmonary toxicity in patients with respiratory distress after gemcitabine chemotherapy, mainly in elderly patients that received high doses of this drug.
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